Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
February 14 2017 - 12:55PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Stemline Therapeutics
Inc. (“Stemline” or the “Company”) (NASDAQ:STML) into potential
breaches of fiduciary duty by the Company’s Board of Directors (the
“Board”).
Stemline, headquartered in New York, NY, is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of oncology therapies. Newman Ferrara’s
investigation focuses on decisions made by the Board, without
shareholder approval, the result of which significantly diminish
shareholder value and do not benefit the Company. Considering the
Company’s lackluster performance since its February 2013 IPO, it is
clear that the Board lacks the ability to fairly assess and oversee
the Company’s direction and leadership.
Current Stemline stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com)
to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170214006153/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024